目的：探讨前列腺癌患者血清中miRNA－32、miRNA－196a、let7i、miRNA－218、miRNA－128的表达差异。方法收集前列癌患者血清，用实时荧光定量PCR检测miRNAs的相对表达含量，并分析与前列腺癌临床病理参数间的关系。结果 miRNA－32、miRNA－196a和miRNA－128在前列腺癌中高表达，let7i和miRNA－218在前列腺癌中低表达。 miRNA－32在前列腺癌患者血清中的含量明显高于对照组（健康者）（ P＜0.05），且分别在病理分期T1～2组与T3～4组比较、Gleason评分≤7组与＞7组比较、淋巴转移有无转移比较中，差异均有统计学意义（ P＜0.05）。结论 miRNA－32作为前列腺癌的诊断标志物具有很高的效能。%Objective To investigate the expression of miRNA-32, miRNA-196a, let7i and miRNA-218, miRNA-128 in serum of patients with prostate cancer.Methods The relative expression level of miRNAs was detected by real-time fluorescence quantitative PCR in serum of patients with prostate cancer.Correlation between marker expres-sion and the clinical pathological parameters of prostate cancer was analyzed.Results High expression of miRNA-32,-196a, and -128 was detected in prostate cancer, while let7i and miRNA-218 showed low expression in prostate canc-er.The level of miRNA-32 in serum of patients with prostate cancer was significantly higher than that in the normal group.Significantly different levels of expression were found in the comparison between pathological staging of T1~2 and T3~4 , between Gleason score less than or equal to 7 and more than 7 and between whether lymph node metastasis was pres-ent(P<0.05).Conclusion miRNA-32 as a diagnosis marker of prostate cancer has a high efficiency.
展开▼
